Abstract
“PET imaging with fluorodeoxyglucose (FDG), integrated with PET/computed tomography (FDG-PET/CT), is an effective management tool of diffuse large B-cell lymphoma (DLBCL). The results of end-of-treatment (EOT) FDG-PET/CT are more accurate for detection of active disease with residual masses on CT. Complete response defined by EOT FDG-PET/CT (PET-CR) correlates with long-term outcome of patients. Treatment efficacy is determined using EOT PET/CT rather than progression-free survival (PFS) for clinical trials assessing novel drugs. If the correlation of EOT PET/CT with PFS is further proven in large studies and meta-analyses, EOT PET-CR could serve as an expedited novel endpoint replacing PFS.”
| Original language | English |
|---|---|
| Pages (from-to) | 307-315 |
| Number of pages | 9 |
| Journal | PET Clinics |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 2019 |
Keywords
- Diffuse large B-cell lymphoma
- End-of-treatment PET-CT
- FDG-PET/CT
- Prediction of outcome
Fingerprint
Dive into the research topics of 'End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver